On 15 October 2014, orphan designation (EU/3/14/1348) was granted by the European Commission to Stemgen S.p.A., Italy, for recombinant human bone morphogenetic protein 4 for the treatment of glioma.
Recombinant human bone morphogenetic protein 4
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.